CD33 Exon 2 skipping oligonucleotide program (Entrada Therapeutics)

N/A

Report date: 2025/03/19 20:00:56

Base Information

Drug NameCD33 Exon 2 skipping oligonucleotide program (Entrada Therapeutics)
Drug Alias NameN/A
ClassificationBiologics
Mechanisms of ActionMyeloid cell surface antigen CD33 modulators
TargetsMyeloid cell surface antigen CD33
Therapy Area/IndicationsNerve Degeneration
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesEntrada Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesEntrada Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsNerve Degeneration

Other Information

ATC CodeN/A
Related LinksN/A